Compare BioNTech SE - ADR (BNTX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Merck & Co., Inc. — how do they compare? BioNTech SE - ADR trades at $90.28 (market cap $22.86B), while Merck & Co., Inc. trades at $124.61 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 13× BioNTech SE - ADR's market cap, and Merck & Co., Inc. pays a 2.82% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | MRK | |
|---|---|---|
Market Cap | $22.86B | $298.31B |
Sector | Health | Health |
52-Week High | $119.34 | $129.52 |
52-Week Low | $83.89 | $77.60 |
Enterprise Value | $6.53B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Merck (MRK) trades at $124.34, showing modest daily gains of 0.25% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with 73.91% gross margins and has beaten earnings expectations in recent quarters. Recent acquisition activity, including the Terns Pharmaceuticals deal announced April 7, 2026, demonstrates strategic pipeline expansion in oncology.
Merck presents a compelling investment case with analyst consensus favoring bullish sentiment (67.57% buy ratings) and a $137.30 price target offering ~10% upside. However, rising debt levels and projected 2026 earnings decline warrant caution. The stock's premium valuation at 34x P/E requires sustained execution to justify current pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
